ENLV
Enlivex Therapeutics Ltd.
There isn't enough reported data to score ENLV yet.
ENLV Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Healthy | |
| Unavailable | |
| Unavailable |
ENLV's profitability is currently healthy. There isn't enough data to rate its revenue, cash flow and balance sheet.
ENLV PE Valuation
ENLV has no meaningful PE right now: it lost money over the past year.
ENLV Forward outlook
There aren't enough analyst estimates for ENLV to show an outlook.
ENLV Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2025 | $6,110.40 | +$6,288.00 |
| Q3 2025 | -$136.80 | +$100.80 |
| Q2 2025 | -$143.52 | +$142.08 |
| Q1 2025 | -$163.20 | +$172.80 |
| Q4 2024 | -$177.60 | +$196.80 |
| Q3 2024 | -$237.60 | +$103.20 |
| Q2 2024 | -$285.60 | +$52.80 |
| Q1 2024 | -$336.00 | +$96.00 |
ENLV has returned to profit: it earned $6,110.40 per share over the past year, after losing money the year before.
ENLV Quarterly Revenue
ENLV's revenue is shrinking: $0 last quarter.
ENLV Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$5.5M | -$4.3M |
| Q1 2026 | -$5.5M | -$816K |
| Q4 2025 | -$2.9M | +$1.2M |
| Q3 2025 | -$2.3M | +$307K |
| Q2 2025 | -$1.2M | +$608K |
| Q1 2025 | -$4.7M | -$103K |
| Q4 2024 | -$4.1M | +$913.7K |
| Q3 2024 | -$2.6M | +$2.8M |
ENLV has burned cash in almost every quarter: −$16M over the past year, against −$13M the year before.
ENLV Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +100% | +101K shares |
| 1 year | +120% | +110K shares |
| 3 years | +162% | +124K shares |
| 5 years | +258% | +145K shares |
| Available history | +372% | +158K shares |
ENLV has 200,827 diluted shares, up 120% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
ENLV Net Leverage
ENLV Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 17.5 | Oversold |
| Stochastic | 0.1 | Oversold |
ENLV's weekly RSI is 18 (oversold) and its Stochastic is 0 (oversold).
ENLV PE vs Healthcare Sector
ENLV has no meaningful PE right now: it lost money over the past year.
ENLV Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.77 | 67% below |
| 20 week MA | $29.6 | 96% below |
| 50 week MA | $142.2 | 99% below |
| 100 week MA | $202.7 | 99% below |
| 200 week MA | $375.6 | 100% below |
ENLV is in a downtrend: it's below all five of its weekly moving averages, and 100% below its 200-week average.
ENLV Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $2,191.2 | $2,505.6 | +14% |
| 2021 | $2,505.6 | $1,488.0 | -41% |
| 2022 | $1,488.0 | $933.6 | -37% |
| 2023 | $933.6 | $648.0 | -31% |
| 2024 | $648.0 | $285.6 | -56% |
| 2025 | $285.6 | $179.5 | -37% |
| 2026 YTD | $179.5 | $1.25 | -99% |
ENLV has finished five years in a row lower, and it's down 99% so far in 2026.